ONCO vs. INAB, APRE, OKUR, SNTI, MIRA, LPCN, BCAB, MEIP, MRKR, and CARM
Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include IN8bio (INAB), Aprea Therapeutics (APRE), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), MIRA Pharmaceuticals (MIRA), Lipocine (LPCN), BioAtla (BCAB), MEI Pharma (MEIP), Marker Therapeutics (MRKR), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry.
Onconetix vs.
Onconetix (NASDAQ:ONCO) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
In the previous week, IN8bio had 2 more articles in the media than Onconetix. MarketBeat recorded 2 mentions for IN8bio and 0 mentions for Onconetix. Onconetix's average media sentiment score of 1.62 beat IN8bio's score of 0.13 indicating that Onconetix is being referred to more favorably in the media.
IN8bio has a consensus price target of $7.75, indicating a potential upside of 2,754.51%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than Onconetix.
IN8bio has a net margin of 0.00% compared to Onconetix's net margin of -2,758.89%. Onconetix's return on equity of 0.00% beat IN8bio's return on equity.
IN8bio received 25 more outperform votes than Onconetix when rated by MarketBeat users.
Onconetix has a beta of 3.17, indicating that its stock price is 217% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.
IN8bio has lower revenue, but higher earnings than Onconetix.
23.9% of Onconetix shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 11.4% of Onconetix shares are held by insiders. Comparatively, 15.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
IN8bio beats Onconetix on 9 of the 14 factors compared between the two stocks.
Get Onconetix News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Onconetix Competitors List
Related Companies and Tools
This page (NASDAQ:ONCO) was last updated on 2/22/2025 by MarketBeat.com Staff
